Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models

Yifei Feng^{1

2

3}, Boshizhang Peng⁴, Yanan Li⁴, Lejia Sun^{1

2

3}, Yueming Sun^{1

2

3}

Affiliations

¹ Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
² The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
³ Colorectal Institute of Nanjing Medical University, Nanjing, China.
⁴ Peking Union Medical College, Beijing, China.

Comment

Yifei Feng et al. Hepatology. 2023.

. 2023 May 1;77(5):E103-E104.

doi: 10.1097/HEP.0000000000000209. Epub 2023 Jan 3.

Yifei Feng^{1

2

3}, Boshizhang Peng⁴, Yanan Li⁴, Lejia Sun^{1

2

3}, Yueming Sun^{1

2

3}

¹ Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
² The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China.
³ Colorectal Institute of Nanjing Medical University, Nanjing, China.
⁴ Peking Union Medical College, Beijing, China.

No abstract available

Comment in

Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys.
Chang D, Truong E, Noureddin M. Chang D, et al. Hepatology. 2023 May 1;77(5):E105-E106. doi: 10.1097/HEP.0000000000000211. Epub 2023 Jan 3. Hepatology. 2023. PMID: 37018138 No abstract available.

Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
Chang D, Truong E, Mena EA, Pacheco F, Wong M, Guindi M, Todo TT, Noureddin N, Ayoub W, Yang JD, Kim IK, Kohli A, Alkhouri N, Harrison S, Noureddin M. Chang D, et al. Hepatology. 2023 Feb 1;77(2):546-557. doi: 10.1002/hep.32655. Epub 2022 Aug 9. Hepatology. 2023. PMID: 35809234

1. Chang D, Truong E, Mena EA, Pacheco F, Wong M, Guindi M, et al. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. Hepatology. 2022; https://doi.org/10.1002/hep.32655. [Epub ahead of print]. - DOI
1. Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, et al. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol. 2021;20:100253.
1. Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology. 2013;57:103–11.
1. Chen T, Guestrin C. XGBoost: a scalable tree boosting system. Knowledge Discovery and Data Mining. 2016;2016:785–94.
1. Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:198–210.e192.